Skip to main content
. 2019 Sep 10;9:13009. doi: 10.1038/s41598-019-49525-y

Figure 5.

Figure 5

Relative risks of microalbuminuria, macroalbuminuria, worsening nephropathy, and end-stage renal disease for sodium-glucose cotransporter 2 inhibitors versus placebo or other antidiabetic drugs. (A) Microalbuminuria. (B) Macroalbuminuria. (C) Worsening nephropathy. (D) End-stage renal disease. CI, confidence interval; RR, relative risk; W, weight.